Compare ORC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORC | DRTS |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2011 | 2021 |
| Metric | ORC | DRTS |
|---|---|---|
| Price | $5.73 | $14.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.50 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 4.5M | 591.7K |
| Earning Date | 04-23-2026 | 05-18-2026 |
| Dividend Yield | ★ 17.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.28 | N/A |
| Revenue Next Year | $5.71 | $699.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.67 | $3.43 |
| 52 Week High | $8.40 | $15.79 |
| Indicator | ORC | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 20.30 | 54.36 |
| Support Level | N/A | $13.73 |
| Resistance Level | $7.47 | $15.01 |
| Average True Range (ATR) | 0.14 | 0.64 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 10.61 | 56.28 |
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.